← Back to guidelines
Cardiology21 papers

Bacterial pneumonia

Last edited: 4/15/2026

Overview

Bacterial pneumonia is an infection of the lung parenchyma caused by bacteria, leading to symptoms such as cough, fever, and respiratory distress. It requires prompt diagnosis and treatment to prevent complications and mortality 1.

Diagnosis

  • Clinical Presentation: Fever, cough with sputum production, dyspnea 1.
  • Laboratory Tests: Complete blood count (CBC) for leukocytosis, C-reactive protein (CRP) elevation 1.
  • Imaging: Chest X-ray showing infiltrates, consolidation, or pleural effusion 1.
  • Microbiological Confirmation: Sputum culture, blood cultures, and urinalysis for signs of infection spread 1.
  • Nephrotoxicity Monitoring: Regular serum creatinine and urinalysis in patients on aminoglycosides 1.
  • Neutropenia Screening: Frequent CBC monitoring in patients receiving high-risk antibiotics 1.
  • Management

  • First-Line Antibiotics: Cephalosporins, penicillins, or aminoglycosides based on local resistance patterns 1.
  • Duration of Therapy: Typically 7-14 days, adjusted based on clinical response and microbiological data 1.
  • Adjunctive Treatments: Oxygen therapy for hypoxemia, mechanical ventilation if respiratory failure occurs 1.
  • Monitoring for Adverse Effects: Regular assessment for nephrotoxicity and neutropenia, especially with aminoglycosides 1.
  • Special Populations

  • Elderly: Increased susceptibility to complications; careful monitoring of renal function and drug dosing adjustments 1.
  • Comorbidities: Patients with underlying conditions like chronic obstructive pulmonary disease (COPD) may require tailored antibiotic choices and closer monitoring 1.
  • Key Recommendations

  • Implement prospective surveillance for adverse drug reactions, particularly nephrotoxicity and neutropenia, in patients treated with aminoglycosides and other high-risk antibiotics (Evidence: Moderate) 1.
  • Ensure thorough monitoring of renal function and complete blood counts in elderly patients and those with comorbidities to prevent complications (Evidence: Moderate) 1.
  • Tailor antibiotic therapy based on local resistance patterns and clinical response, extending beyond a one-size-fits-all approach (Evidence: Expert opinion) 1.
  • References

    1 Timm EG, Welage LS, Walawander CA, Sayers JF, Karpiuk EL, Davis TD et al.. Adverse drug reaction reporting in a multicenter surveillance study. The Annals of pharmacotherapy 1995. link

    Original source

    1. [1]
      Adverse drug reaction reporting in a multicenter surveillance study.Timm EG, Welage LS, Walawander CA, Sayers JF, Karpiuk EL, Davis TD et al. The Annals of pharmacotherapy (1995)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG